-
-
-
-
-
-
-
Neurocrine Biosciences to Participate at Investor Conferences in June
-
-
-
-
-
-
-
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
-
-
-
-
-
-
-
Biogen (BIIB) May Need More M&A Following AD Failure - Analysts
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): Survey Shows Ingrezza To Be Restricted - Jefferies
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX): Austedo Approved, Ingrezza Next - Jefferies
-
-
-
-
-
-
-
Neurocrine Bio's (NBIX) Valbenazine Data Better Than Teva's (TEVA)- Jefferies
-
-
-
-
-
-
-
Neurocrine Biosciences (NBIX) Prices 6.9M Shares at $36/Share
-
72,063 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

